Supplementary Figure S5 from Comutations and KRAS<sup>G12C</sup> Inhibitor Efficacy in Advanced NSCLC

Marcelo V. Negrao,Haniel A. Araujo,Giuseppe Lamberti,Alissa J. Cooper,Neal S. Akhave,Teng Zhou,Lukas Delasos,J. Kevin Hicks,Mihaela Aldea,Gabriele Minuti,Jacobi Hines,Jacqueline V. Aredo,Michael J. Dennis,Turja Chakrabarti,Susan C. Scott,Paolo Bironzo,Matthias Scheffler,Petros Christopoulos,Albrecht Stenzinger,Jonathan W. Riess, So Yeon Kim,Sarah B. Goldberg,Mingjia Li,Qi Wang,Yun Qing,Ying Ni,Minh Truong Do,Richard Lee,Biagio Ricciuti,Joao Victor Alessi,Jing Wang, Blerina Resuli,Lorenza Landi,Shu-Chi Tseng,Mizuki Nishino,Subba R. Digumarthy,Waree Rinsurongkawong,Vadeerat Rinsurongkawong,Ara A. Vaporciyan,George R. Blumenschein,Jianjun Zhang,Dwight H. Owen,Collin M. Blakely,Giannis Mountzios,Catherine A. Shu,Christine M. Bestvina,Marina Chiara Garassino,Kristen A. Marrone,Jhanelle E. Gray,Sandip Pravin Patel,Amy L. Cummings,Heather A. Wakelee,Juergen Wolf,Giorgio Vittorio Scagliotti,Federico Cappuzzo,Fabrice Barlesi,Pradnya D. Patil,Leylah Drusbosky,Don L. Gibbons,Funda Meric-Bernstam, J. Jack Lee,John V. Heymach,David S. Hong,Rebecca S. Heist,Mark M. Awad,Ferdinandos Skoulidis

openalex（2023）

引用 0|浏览0

暂无评分

摘要

Survival outcomes according to KEAP1 and STK11 co-mutation status: A) Cohort A; B) Cohort B; C) further subclassifying KEAP1MUT tumors according to STK11 mutation status; D) PFS and OS according to STK11 co-mutation status in KSCWT tumors in the overall study cohort.

查看译文

关键词

Mutation Analysis,Tumor Models,Cancer Progression,Intratumor Heterogeneity

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要

Supplementary Figure S5 from Comutations and KRAS&lt;sup&gt;G12C&lt;/sup&gt; Inhibitor Efficacy in Advanced NSCLC

Supplementary Figure S5 from Comutations and KRAS<sup>G12C</sup> Inhibitor Efficacy in Advanced NSCLC